KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.

Laure Gossec, Laura C Coates, Robert B M Landewé, Philip J Mease, Joseph F Merola, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Fabian Proft, Nadine Goldammer, Myriam Manente, Barbara Ink, Rajan Bajracharya, Jason Coarse, Iain B McInnes

Rheumatology (Oxford) 65(5) keag118

PMID41838419
PMCIDPMC13198880
DOI10.1093/rheumatology/keag118
发表日期2026-03-16
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:图注未提示 KM 曲线;Figure 1:图注未提示 KM 曲线;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线;Figure 4:图注未提示 KM 曲线。
摘要

摘要

OBJECTIVES: Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has demonstrated tolerability and clinical efficacy in patients with PsA. Here, we report an additional year of safety and efficacy of bimekizumab treatment to 3 years. METHODS: BE OPTIMAL [NCT03895203; biologic DMARD (bDMARD)-naïve] and BE COMPLETE [NCT03896581; prior inadequate response/intolerance to TNF inhibitors (TNFi-IR)] assessed s.c. bimekizumab 160 mg every 4 weeks in patients with PsA. Study completers could enrol in the BE VITAL open-label extension (NCT04009499). Outcomes were reported as observed, or using modified non-responder or multiple imputation, to 3 years. RESULTS: Overall, 546/299 (76.7/74.8%) bDMARD-naïve/TNFi-IR patients randomized to bimekizumab or placebo at baseline (Bimekizumab Total group) completed year 3. Treatment-emergent adverse event rates [exposure-adjusted incidence rate/100 patient-years (95% CI)] for bimekizumab-treated patients through 3 years were 164.2 (152.7-176.3) in bDMARD-naïve and 88.6 (79.1-98.9) in TNFi-IR patients, consistent with those at year 1 with no new safety signals identified. Response rates for efficacy outcomes were sustained up to 3 years; at year 1 and year 3, respectively, 56.1/50.4% and 53.2/55.2% of bDMARD-naïve/TNFi-IR patients achieved ACR50, 61.8/58.2% and 59.5/59.1% achieved swollen joint count resolution, and 64.7/66.2% and 61.9/67.5% had 100% improvement from baseline in Psoriasis Area and Severity Index. Responses for other efficacy measures were similarly sustained and consistent in bDMARD-naïve and TNFi-IR patients. CONCLUSION: Bimekizumab demonstrated sustained high levels of efficacy and tolerability to 3 years, supporting its suitability for long-term treatment in bDMARD-naïve and TNFi-IR patients with PsA. TRIAL REGISTRATION: BE OPTIMAL: NCT03895203; BE COMPLETE: NCT03896581; BE VITAL: NCT04009499.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical Abstract无图注
非 KM Figure
Figure 1Joint outcomes to 3 years (mNRI, OC). Randomized set. Bimekizumab Total group includes bimekizumab-randomized patients and placebo-randomized patients who switched to bimekizumab at week 16. Data reported to 3 years (week 160 in BE OPTIMAL and week 156 in BE COMPLETE). mNRI considered all visits following discontinuation due to AEs or lack of efficacy as non-response; all other missing data were imputed with multiple imputation and the response derived from the imputed values. Error bars represent 95% CIs. ACR50/70: ≥50/70% improvement from baseline in ACR response criteria; AE: adverse event; bDMARD: biologic DMARD; BKZ: bimekizumab; mNRI: modified non-responder imputation; OC: observed case; PBO: placebo; Q4W: every 4 weeks; SJC: swollen joint count; TNFi-IR: prior inadequate response or intolerance to TNF inhibitors
非 KM Figure
Figure 2Skin and nail outcomes to 3 years (mNRI, OC). Randomized set. Bimekizumab Total group includes bimekizumab-randomized patients and placebo-randomized patients who switched to bimekizumab at week 16. Data reported to 3 years (week 160 in BE OPTIMAL and week 156 in BE COMPLETE). mNRI considered all visits following discontinuation due to AEs or lack of efficacy as non-response; all other missing data were imputed with multiple imputation and the response derived from the imputed values. a In patients with ≥3% BSA at baseline; b In patients with nail psoriasis (mNAPSI >0) at baseline. Error bars represent 95% CIs. AE: adverse event; bDMARD: biologic DMARD; BKZ: bimekizumab; BSA: body surface area; mNAPSI: modified Nail Psoriasis Severity Index; mNRI: modified non-responder imputation; OC: observed case; PASI90/100: ≥90/100% improvement from baseline in Psoriasis Area and Severity Index; PBO: placebo; Q4W: every 4 weeks; TNFi-IR: prior inadequate response or intolerance to TNF inhibitors
非 KM Figure
Figure 3Composite outcomes to 3 years (mNRI, OC). Randomized set. Bimekizumab Total group includes bimekizumab-randomized patients and placebo-randomized patients who switched to bimekizumab at week 16. Data reported to 3 years (week 160 in BE OPTIMAL and week 156 in BE COMPLETE). mNRI considered all visits following discontinuation due to AEs or lack of efficacy as non-response; all other missing data were imputed with multiple imputation and the response derived from the imputed values. Error bars represent 95% CIs. a In patients with ≥3% BSA at baseline. ACR50+PASI100: ≥50% improvement from baseline in ACR response criteria+100% improvement from baseline in Psoriasis Area and Severity Index; AE: adverse event; bDMARD: biologic DMARD; BKZ: bimekizumab; BSA: body surface area; MDA: minimal disease activity; mNRI: modified non-responder imputation; OC: observed case; PBO: placebo; Q4W: every 4 weeks; TNFi-IR: prior inadequate response or intolerance to TNF inhibitors; VLDA: very low disease activity
非 KM Figure
Figure 4Patient-reported outcomes to 3 years (mNRI, OC). Randomized set. Bimekizumab Total group includes bimekizumab-randomized patients and placebo-randomized patients who switched to bimekizumab at week 16. Data reported to 3 years (week 148 for PsAID-12 or week 160 for HAQ-DI in BE OPTIMAL and week 156 in BE COMPLETE). mNRI considered all visits following discontinuation due to AEs or lack of efficacy as non-response; all other missing data were imputed with multiple imputation and the response derived from the imputed values. Error bars represent 95% CIs. a PsAID-12 clinically meaningful improvement defined as decrease from baseline of ≥3 in patients with PsAID-12 ≥3 at baseline; data reported at week 40 (year 1) and week 88 (year 2) for BE COMPLETE; b HAQ-DI MCID defined as decrease from baseline of ≥0.35 in patients with HAQ-DI of ≥0.35 at baseline; data reported at week 100 (year 2) for BE COMPLETE. AE: adverse event; bDMARD: biologic DMARD; BKZ: bimekizumab; HAQ-DI: Health Assessment Questionnaire-Disability Index; MCID: minimal clinically important difference; mNRI: modified non-responder imputation; OC: observed case; PBO: placebo; PsAID-12: Psoriatic Arthritis Impact of Disease 12-item questionnaire; Q4W: every 4 weeks; TNFi-IR: prior inadequate response or intolerance to TNF inhibitors
非 KM Figure